ClinicalTrials.gg
RecruitingNCT06433921Updated Nov 6, 2026

A Study to Compare the Relative Potency of Salbutamol Administered Via Metered Dose Inhalers (MDI) Containing Propellants HFA-152a to HFA-134a in Mild Asthmatics Aged 18 to 65 Inclusive

A Phase 1 interventional study of Salbutamol HFA-152a and Salbutamol HFA-134a in Asthma and Mild Asthma, sponsored by GlaxoSmithKline. Recruiting at 1 site in United Kingdom. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-06.

Sponsored by GlaxoSmithKline · Phase 1, Interventional, and Other

How we know

From the registry’s dates

  • Started Aug 2024; still recruiting 2 years 3 months later.
Updated Nov 6, 2026Primary completion movedStudy completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
84
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 72 studies testing albuterol in Asthma — 8 open to participants now, 9 under way, 1 of them phase 3. Albuterol · Asthma.

Planned enrollment
30th of 72
84 · median 63
Started
2024
with 8 others
Phase 1
7 of 72
2 open now
Registered
64th of 72
by date
Lead sponsor
8 of 72
GlaxoSmithKline

Among the 72 studies testing albuterol in Asthma, this one is the 30th largest by planned enrollment, is one of 9 that started in 2024, is one of 7 in phase 1, and was the 64th registered.

Asthma

4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.

Browse Asthma studies →

Open to participants now

8 of the 72 studies testing albuterol in Asthma are open now, in 6 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About albuterol

Albuterol: first FDA approval 1981 (PROVENTIL). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 416 Asthma studies recruiting now, 141 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 146 take children under 18; 105 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 72 studies testing albuterol in Asthma, or all of them as a file.
02

Study summary

The primary objectives of the study are: Part 1: to characterize the potency and variability of dose response on efficacy (Provocative concentration of methacholine causing at least a 20% fall in forced expiratory volume (FEV1) [PC20]) of salbutamol administered via MDI with salbutamol HFA-134a or salbutamol HFA-152a in participants with mild asthma. Part 2: to compare the comparative dose response on efficacy (PC20) of salbutamol when administered via MDI with salbutamol HFA-134a or salbutamol HFA-152a in participants with mild asthma.

03

Conditions studied

  • Asthma
  • Mild Asthma

Browse trials for

Keywords

  • Salbutamol
  • Propellant HFA-152a
  • Propellant HFA-134a
  • Metered dose inhalers
  • Mild asthma
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female; females may be of , of nonchildbearing potential, or .
  2. Participant must be 18 to 65 years of age inclusive, at the time of screening.
  3. ≥50 kg, at the time of screening.
  4. (BMI) with 19.0-35.0 kg/m2 inclusive, at the time of screening.

4. Documented history of asthma ≥ 6 months. 5. Receiving 1 of following asthma treatments, at a stable dose, for at least 12 weeks prior to the screening visit and is anticipated to remain stable for the duration of the study: i. Short-acting beta-agonist (SABA) only. ii. Daily maintenance low-dose inhaled (ICS) (defined as 100-250 μg/day fluticasone propionate or equivalent plus or minus SABA which is anticipated to remain stable for the duration of the study.

iii. Daily maintenance low-dose ICS + Long-acting beta-2 agonist (LABA) therapy (low-dose ICS defined as 100-250 μg/day fluticasone propionate or equivalent as defined by GINA [GINA, 2023]) plus or minus SABA, which is anticipated to remain stable for the duration of the study.

6. No severe asthma exacerbations within 6 months prior to screening and ≤1 severe exacerbation during the 12 months prior to screening.

7. Pre-bronchodilator ≥80% of predicted, at screening. 8. PC20 to methacholine of ≤8 mg/mL, at screening. 9. Participants should be able to withhold SABA for ≥12 hours and LABA-containing medications for ≥48 hours for the purposes of performing the spirometry and methacholine challenge at screening and during the study visits (treatment periods).

10. A female participant is eligible to participate if she is not pregnant or breastfeeding, and Is a woman of woman of nonchildbearing potential (WONCBP) OR ii. Is a woman of child bearing potential (WOCBP) and using a method that is highly effective.

11. Provide signed which includes compliance with the requirements and restrictions listed in the informed consent form and in this protocol.

12. Non-smokers who have not used any tobacco containing-products within 12 months prior to study start, and with a total pack year history of ≤10 pack years.

Exclusion criteria

Exclusion Criteria:

  1. Medical Conditions

    1. A history of life-threatening asthma or asthma that is unstable in the opinion of the investigator.
    2. A history of respiratory diseases to include (but not limited to): pneumothorax, pulmonary fibrotic disease, bronchopulmonary dysplasia, chronic bronchitis, cystic fibrosis, bronchiectasis, interstitial lung disease, emphysema, , tuberculosis, or other respiratory abnormalities other than asthma.
    3. Asymptomatic gallstones.
    4. History or current evidence of hematologic, neurologic, psychiatric, or other diseases that, in the opinion of the investigator, would put the participant at risk through study participation, or would affect the study analyses if the disease exacerbates during the study.
    5. Recent eye surgery or any other condition in which raised intracranial pressure (caused by forceful exhalation) would be harmful.
    6. Current use of cholinesterase inhibitor medication e.g., to treat myasthenia gravis.
  2. Exposure to more than 4 new chemical entities within 12 months prior to the first dosing day or participation in a clinical study within 30 days of study start, or 5 half-lives of study drug if that is longer.
  3. Participants who are currently or in the last 15 days have worked nightshifts.
  4. Regular alcohol consumption within 6 months prior to the study defined as: an average weekly intake of >21 units for males or >14 units for females.
  5. A positive test result for drugs of abuse (including tetrahydrocannabinol) at screening or Day -1.
  6. Use of combustible tobacco products, and non-combustible nicotine delivery systems, inclusive of cigarettes, cigars, pipes, and materials used to "vape" within 12 months prior to the start of the study.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
84 participants (estimated)

Study arms

  • Experimental
    Part 1

    Part 1 will consist of a 7 treatment, 7 period cross-over evaluation with all participants receiving the following treatments once, randomized to varying pre-specified sequences of: * Zero dose (placebo of both salbutamol HFA-134a and salbutamol HFA-152a) * 100 μg salbutamol HFA-134a * 200 μg salbutamol HFA-134a * 400 μg salbutamol HFA-134a * 100 μg salbutamol HFA-152a * 200 μg salbutamol HFA-152a * 400 μg salbutamol HFA-152a A minimum of a 2-day and maximum of a 7-day methacholine washout will separate each treatment period.

    Drug: Salbutamol HFA-152a · Drug: Salbutamol HFA-134a · Drug: Placebo

  • Experimental
    Part 2

    Part 2 will consist of a 7 treatment, 7-way cross-over with all participants receiving the following treatments given once, randomized to varying pre-specified sequences of: * Zero dose (placebo of both salbutamol HFA-134a and salbutamol HFA-152a) * 100 μg salbutamol HFA-134a * 200 μg salbutamol HFA-134a * 400 μg salbutamol HFA-134a * 100 μg salbutamol HFA-152a * 200 μg salbutamol HFA-152a * 400 μg salbutamol HFA-152a A minimum of a 3-day and maximum of a 7-day methacholine washout will separate each treatment period.

    Drug: Salbutamol HFA-152a · Drug: Salbutamol HFA-134a · Drug: Placebo

Interventions

  • DrugAlbuterolStudies of AlbuterolAlbuterol pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    A single 100, 200 or 400 μg dose, given as 1, 2 or 4 × 100 μg actuations (exvalve) at 20 second intervals.

  • DrugAlbuterolStudies of AlbuterolAlbuterol pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    A single 100, 200 or 400 μg dose, given as 1, 2 or 4 × 100 μg actuations (exvalve) at 20 second intervals.

  • DrugPlacebo

    A single placebo HFA-152a suspension or placebo HFA-134a suspension dose, given as at 20 second intervals.

06

What researchers measure

Primary outcomes

  1. Part 1 & Part 2: Provocative concentration of methacholine causing at least a 20% fall in FEV1 (PC20)

    Time frame: Up to 11 weeks

Secondary outcomes

  1. Part 1 & Part 2: Peak QTc Interval

    Time frame: Up to 11 weeks

  2. Part 1 & Part 2: Peak Heart Rate (HR)

    Time frame: Up to 11 weeks

  3. Part 1 & Part 2: Minimum Serum Potassium

    Time frame: Up to 11 weeks

  4. Part 1: Maximum Observed Plasma Concentration (Cmax)

    Time frame: Up to 11 weeks

  5. Part 1: Time to Reach Cmax (Tmax)

    Time frame: Up to 11 weeks

  6. Part 1: Area Under the Plasma Concentration-time Curve up to Last Time With Concentrations Above the Lower Limit of Quantification (LLOQ) (AUC[0-last])

    Time frame: Up to 11 weeks

  7. Part 1 & Part 2: Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs)

    Time frame: Up to 11 weeks

  8. Part 1 & Part 2: Absolute Values for 12-lead Electrocardiogram (ECG) Recording of HR

    Time frame: Up to 11 weeks

  9. Part 1 & Part 2: Absolute Values for 12-lead ECGs Recording of Intervals

    Intervals recorded: - PR. - QRS. - QT. - QTc

    Time frame: Up to 11 weeks

  10. Part 1 & Part 2: Change from Baseline for Post-dose 12-lead ECGs Recording of HR

    The 3 predose measures will be recorded and will be averaged for HR to derive 1 baseline value.

    Time frame: Baseline and up to 11 weeks

  11. Part 1 & Part 2: Change from Baseline for Post-dose 12-lead ECGs Recording of Intervals

    The 3 predose measures will be recorded and will be averaged for QTc interval to derive 1 baseline value. Intervals recorded: - PR. - QRS. - QT. - QTc

    Time frame: Up to 11 weeks

  12. Part 1 & Part 2: Number of Participants with Clinically Significant Changes in Clinical Laboratory Parameters

    Time frame: Up to 11 weeks

  13. Part 1 & Part 2: Absolute Values of Vital Signs (Systolic and Diastolic Blood Pressure)

    Time frame: Up to 11 weeks

  14. Part 1 & Part 2: Absolute Values of Vital Signs (Pulse Rate)

    Time frame: Up to 11 weeks

07

Study locations

1 of 1 sites recruiting
  • GSK Investigational Site
    Manchester, Greater Manchester M23 9QZ, United Kingdom
    Recruiting
08

References and documents

Publications

  • Moreira S, Clow L, Coles-Piper E, Donald A, Janson C, Singh D, Slade D, Tiwari P, Weng S, Plank M. Developing low-carbon salbutamol MDI: assessment of relative bioavailability and pharmacodynamic relative potency of salbutamol MDI with propellant HFA-152a. BMJ Open Respir Res. 2026 Jun 17;13(1):e004036. doi: 10.1136/bmjresp-2025-004036. PubMed 42309649 ↗

Individual participant data

Plan to share: Yes — Qualified researchers may request access to anonymized individual patient-level data (IPD) and related study documents of the eligible studies via the Data Sharing Portal. Details on GSK's data sharing criteria can be found at: https://www.gsk.com/en-gb/innovation/trials/data-transparency/

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.

Access criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.

Data sharing details ↗ · www.gsk.com

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2024 (actual). Primary completion is estimated for Apr 2027, 32 months after the start.

Of 173 industry-sponsored phase 1 interventional studies under Asthma, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 12. This study's planned 32 months is above that.

Counting every sponsor, half of 200 studies reached it within 6 months; a quarter within 3 and three quarters within 14.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 6, 2026: primary completion Feb 2027 → Apr 2027 and completion Feb 2027 → Apr 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 23, 2024
First posted
May 30, 2024
StartActual
Aug 14, 2024
Primary completionEst.
Apr 16, 2027was Feb 2027
CompletionEst.
Apr 16, 2027was Feb 2027
Last update
Nov 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added, 1 site removed
Show site
  • GSK Investigational Site · Manchester, United Kingdom
Show 1 removed
  • GSK Investigational Site · Manchester, United Kingdom
Nov 6, 2026
Primary completion
Feb 26, 2027→Apr 16, 2027
Nov 6, 2026
Study completion
Feb 26, 2027→Apr 16, 2027
Nov 6, 2026
Show all 1 update
  1. Nov 6, 2026
    1 site added, 1 site removed
    Show site
    • GSK Investigational Site · Manchester, United Kingdom
    Show 1 removed
    • GSK Investigational Site · Manchester, United Kingdom
    Primary completion Feb 26, 2027→Apr 16, 2027
    Study completion Feb 26, 2027→Apr 16, 2027
    + 3 other changes: identifiers, verification date and references

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06433921
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
May 30, 2024
Start date
Aug 14, 2024
Primary completion
Apr 16, 2027 (estimated)
Completion
Apr 16, 2027 (estimated)
Last update
Nov 6, 2026

Study contacts

US GSK Clinical Trials Call Center
Contact
GSKClinicalSupportHD@gsk.com
877-379-3718
EU GSK Clinical Trials Call Center
Contact
GSKClinicalSupportHD@gsk.com
+44 (0) 20 89904466

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Albuterol

Start the discussion